Pharmacy Voice chief executive Rob Darracott spoke exclusively to C+D about why the sector should rethink how medicine use reviews (MURs) are delivered, 11 years after they were first introduced.
Mr Darracott made the comments in the wake of allegations made by the Guardian earlier this month (April 13) that Boots encourages its pharmacists to carry out unnecessary MURs for profit – claims the multiple told C+D it "doesn't recognise".
Do you think MURs should be reformed?
We want to hear your views, but please express them in the spirit of a constructive, professional debate. For more information about what this means, please click here to see our community principles and information
The views and opinions discussed during this video news blog represent those of the speakers and not of Actavis UK Ltd Actavis
Reporting forms and information can be found at http://www.mhra.gov.uk/yellowcard
Adverse events can also be reported to Actavis on 01271 385257
* ‘Patient safety is Actavis’ primary concern and we encourage healthcare professionals and patients to report any adverse event which may occur in relation to an Actavis product. An adverse event includes reports of any side effect, product misuse, abuse or overdose, including inappropriate use by children or women who are pregnant or breast-feeding. It also includes reports of a product that was used for something other than the intended purpose or was ineffective, or was given with another medicine. Complaints relating to the product can also be reported.’